Tactile Systems Technology, Inc. (FRA:3L3)
Germany · Delayed Price · Currency is EUR | Market Cap | 478.20M +66.9% |
| Revenue (ttm) | 306.63M +17.2% |
| Net Income | 21.76M +64.5% |
| EPS | 0.96 +72.9% |
| Shares Out | n/a |
| PE Ratio | 21.59 |
| Forward PE | 17.58 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 25 |
| Open | 20.80 |
| Previous Close | 20.40 |
| Day's Range | 20.80 - 20.80 |
| 52-Week Range | 12.60 - 28.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 2, 2026 |
About FRA:3L3
Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema, phlebolymphedema, lipedema, venous insufficiencies, and other types of edema and leg ulcers; Entre Plus System, a pneumatic compression device for the at-home treatment of lymphedema, chronic edema, venous insufficiency, and chronic wounds. The company also provides Nimbl, a pneumatic comp... [Read more]
Financial Performance
In 2025, FRA:3L3's revenue was $329.52 million, an increase of 12.47% compared to the previous year's $292.98 million. Earnings were $19.09 million, an increase of 12.54%.
Financial numbers in USD Financial StatementsNews
Tactile Medical to Release Third Quarter of Fiscal Year 2026 Financial Results on November 2, 2026
MINNEAPOLIS, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chro...
Tactile Systems price target lowered to $35 from $39 at BTIG
BTIG lowered the firm’s price target on Tactile Systems (TCMD) to $35 from $39 and keeps a Buy rating on the shares as part of a broader research note previewing…
Tactile Systems Technology Earnings Call Transcript: Q2 2026
Q2 2026 saw 9% revenue growth to $85.7M, led by lymphedema strength and improved profitability. Guidance was raised to $360–$366M for the year, with lymphedema growth offsetting temporary AffloVest inventory headwinds. Cash remains strong at $69.9M.
Tactile Systems Technology Earnings release: Q2 2026
Tactile Systems Technology released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Tactile Systems Technology Quarterly report: Q2 2026
Tactile Systems Technology has published its Q2 2026 quarterly earnings report on August 10, 2026.
Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026
MINNEAPOLIS, July 21, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chro...
Tactile Medical Enters Exclusive U.S. Distribution Agreement with ElastiMed for its MyoSleeve™ Wearable Compression Device for VA and DoD Patients
Discreet, Battery-Powered Device Reaches Patients at Earlier Stages of Disease Progression Discreet, Battery-Powered Device Reaches Patients at Earlier Stages of Disease Progression
Tactile Systems Technology Transcript: 46th Annual William Blair Growth Stock Conference
The company leads in chronic swelling and lung disease markets, leveraging innovative head-to-toe compression therapies and digital diagnostics to address large, underserved populations. Recent product launches, acquisitions, and favorable policy changes support strong growth and market leadership.
Tactile Medical Launches Next-Generation AffloVest® Airway Clearance Therapy
MINNEAPOLIS, June 02, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chro...
Tactile Medical to Present at the William Blair 46th Annual Growth Stock Conference
MINNEAPOLIS, May 20, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chron...
Tactile Systems upgraded to Buy from Neutral at B. Riley
B. Riley analyst Anderson Schock upgraded Tactile Systems (TCMD) to Buy from Neutral with a price target of $36, up from $32.
Tactile Systems upgraded to Buy from Neutral at B. Riley
B. Riley upgraded Tactile Systems (TCMD) to Buy from Neutral with a price target of $36, up from $32. Tactile Systems reported a top and bottom line beat for Q1,…
Tactile Systems price target raised to $40 from $38 at BTIG
BTIG raised the firm’s price target on Tactile Systems (TCMD) to $40 from $38 and keeps a Buy rating on the shares. The firm is positive on the company’s earnings…
Tactile Systems Technology Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 23% year-over-year to $75.3 million, with strong gains in both lymphedema and airway clearance segments. Gross margin expanded to 76.5%, and adjusted EBITDA improved to $3.7 million. Full-year guidance was raised, reflecting confidence in commercial execution and the LymphaTech acquisition.
Tactile Systems Technology Earnings release: Q1 2026
Tactile Systems Technology released its Q1 2026 earnings on May 4, 2026, summarizing the period's financial results.
Tactile Systems Technology Quarterly report: Q1 2026
Tactile Systems Technology has published its Q1 2026 quarterly earnings report on May 4, 2026.
Tactile Systems Technology, Inc. Reports First Quarter 2026 Financial Results
MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chron...
Tactile Medical to Release First Quarter of Fiscal Year 2026 Financial Results on May 4, 2026
MINNEAPOLIS, April 20, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chr...
Tactile Systems Technology Proxy statement: Proxy filing
Tactile Systems Technology filed a proxy statement on March 25, 2026, providing details for shareholder voting and corporate governance matters.
Tactile Systems Technology Proxy statement: Proxy filing
Tactile Systems Technology filed a proxy statement on March 25, 2026, providing details for shareholder voting and corporate governance matters.
Tactile Systems Technology Proxy statement: Proxy Filing
Tactile Systems Technology filed a proxy statement on March 10, 2026, providing details for shareholder voting and corporate governance matters.
Tactile Systems appoints Andrea Pearson to Board of Directors
Tactile Systems (TCMD) Technology announced the appointment of Andrea Pearson to the Company’s Board of Directors and as a member of the Compliance & Reimbursement and Nominating & Corporate Governanc...
Tactile Medical Strengthens Board of Directors with Appointment of Andrea Pearson
MINNEAPOLIS, March 09, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chr...
Tactile Systems price target raised to $40 from $32 at Lake Street
Lake Street analyst Ben Haynor raised the firm’s price target on Tactile Systems (TCMD) to $40 from $32 and keeps a Buy rating on the shares. Tactile posted “massive upside”…
Tactile Systems price target raised to $32 from $16 at B. Riley
B. Riley raised the firm’s price target on Tactile Systems (TCMD) to $32 from $16 and keeps a Neutral rating on the shares. While the Q4 results and 2025 execution…